TBC1D30 also has been shown to be highly methylated in colorectal cancer. NELL1 has been shown to be a diagnostic marker of both Barrett's esophagus and colorectal cancer, and hypermethylation of ...

Many people haven’t heard of Barrett’s Esophagus, but it’s a serious condition that can be a warning sign for a deadly cancer ...

AND YOUR CHANCE OF GETTING CANCER CAN ALSO BE ELIMINATED. BUT MOST PEOPLE WHO HAVE BARRETT’S ESOPHAGUS TODAY, MILLIONS OF AMERICANS RIGHT NOW ARE WALKING AROUND WITH IT HAVE NO IDEA THEY HAVE IT.

In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing ...

Castle Biosciences has signed an agreement to acquire GI health company Previse, which was developed by specialists at Johns Hopkins University School of Medicine in Baltimore. Previse is focused on ...

2:45-3:30 p.m. The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in ...

Castle Biosciences, Inc, a leading diagnostics company improving health through innovative tests that guide patient care, announced it has signed a definitive agreement to acquire Capsulomics, Inc, ...

CDx Diagnostics announced today that new clinical data supporting the utility of the WATS3D test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium ...

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled,“The ...

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development ...